Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. has notified the SEC that it is unable, without unreasonable effort or expense, to file its Form 10-K for the fiscal year ended December 31, 2025 by the March 16, 2026 deadline due to the classification of inter-company transactions and balances. The company anticipates filing within the fifteen-day grace period provided by Rule 12b-25, but states there is no assurance on timing.
AirSculpt Technologies plans to file a Form 12b-25 to delay its Form 10-K for fiscal 2025, citing the need for more time to complete the classification of inter-company transactions and balances. The company expects to file the annual report within the 15‑day grace period.
AirSculpt released preliminary, unaudited results showing fiscal 2025 revenue of $151.8 million and fourth quarter 2025 revenue of $33.4 million, with same-store revenue down about 16% in the quarter but improving to down single digits in December. For first quarter 2026, it expects revenue of $38.5–$39.5 million, implying roughly flat same-store revenue at the midpoint after positive comparable sales in February. As of March 13, 2026, cash was $13.0 million and debt was $46.0 million, which the company characterizes as a strong balance sheet and enhanced liquidity.
Aaron Rollins filed a Schedule 13D reporting beneficial ownership of 14,721,062 shares of Airsculpt Technologies, Inc., representing 23.6% of its common stock. He holds sole voting and dispositive power over these shares, reflecting his role as founder and former CEO and Executive Chairman.
Rollins states that his stake comes from equity compensation for his executive roles and from personal open-market purchases, including 152,118 shares bought for about $473,837.49, excluding commissions. He is actively evaluating strategic alternatives for his investment, which may include buying more shares, selling shares, seeking board representation, proposing strategic or change-of-control transactions, or advocating changes to strategy, governance, management, or capital allocation. He has not traded in the past 60 days and notes no contracts or arrangements relating to the issuer’s securities.
Airsculpt Technologies, Inc. major shareholder Jorey Chernett reported an open-market purchase of 88,000 shares of Common Stock at a weighted average price of $2.15 per share. The shares were bought in multiple trades between $2.11 and $2.25 per share. Following this transaction, Chernett directly owns 6,486,211 shares, so the new purchase increases an already large position by a relatively small proportion.
Airsculpt Technologies, Inc. major holder Jorey Chernett bought additional shares of the company. On this Form 4, Chernett reported an open-market purchase of 45,600 shares of common stock at a weighted average price of about $2.00 per share, increasing his direct holdings to 6,398,211 shares.
Airsculpt Technologies, Inc. Schedule 13G/A shows that Jorey Chernett beneficially owned 6,781,811 shares of Common Stock as of the close of business on March 4, 2026, representing 10.79% of the class. The percentage is calculated using 62,436,670 Shares outstanding as of November 6, 2025, as disclosed in the issuer's Form 10-Q.
The filing states voting and dispositive power are held solely by the Reporting Person for the listed shares and that some of the shares are underlying currently exercisable call options.
Airsculpt Technologies, Inc. disclosed that 10% owner Jorey Chernett bought a total of 110,000 shares of common stock in open-market purchases. He acquired 80,000 shares at a weighted-average price of $1.71 on March 3 and 30,000 shares at $1.87 on March 4. According to the filing, these were executed in multiple trades at prices ranging from $1.67 to $1.77 and from $1.86 to $1.88. Following these purchases, Chernett directly owns 6,352,611 Airsculpt shares.
Airsculpt Technologies, Inc. major shareholder Jorey Chernett filed an initial Form 3 showing existing holdings in the company. The filing lists direct ownership of call options covering 429,200 shares and 6,242,611 shares of common stock, both as of the reported date, reflecting more than 10% beneficial ownership.
Parian Ultreia reports a significant passive stake in Airsculpt Technologies, Inc. The firm reports beneficial ownership of 3,180,000 shares of AirSculpt Technologies, representing 5.09% of the class, with sole voting and dispositive power over all reported shares as of the event date.
The filer certifies the shares were not acquired and are not held to change or influence control of Airsculpt Technologies, but instead as a passive investment. No other persons or subsidiaries are reported as having beneficial ownership or group status in connection with this holding.
Airsculpt Technologies, Inc. (AIRS) received an amended beneficial ownership report from SW Investment Management LLC and Partners LP. The filing states that, as of the event date, each reporting person beneficially owns 0 shares of Airsculpt common stock, representing 0.0% of the class, based on 62,440,000 shares outstanding.
SW Investment Management LLC is described as the investment manager and general partner of Partners LP, but both entities report no sole or shared voting or dispositive power over any Airsculpt shares. The signatory certifies that any securities referenced were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.